Current status and challenges of immunotherapy in ALK rearranged NSCLC

Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase inhibitors (TKIs) but prone to drug resistance. Meanwhile, ALK rearranged NSCLC has poor response to single immunotherapy. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Rongbin, Yu, Yingying, Shen, Mo, Lv, Dongqing, He, Susu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795041/
https://www.ncbi.nlm.nih.gov/pubmed/36591504
http://dx.doi.org/10.3389/fonc.2022.1016869
_version_ 1784860166827540480
author Qi, Rongbin
Yu, Yingying
Shen, Mo
Lv, Dongqing
He, Susu
author_facet Qi, Rongbin
Yu, Yingying
Shen, Mo
Lv, Dongqing
He, Susu
author_sort Qi, Rongbin
collection PubMed
description Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase inhibitors (TKIs) but prone to drug resistance. Meanwhile, ALK rearranged NSCLC has poor response to single immunotherapy. Here we mainly describe the immune escape mechanisms of ALK mutated NSCLC and the role of related biomarkers. Additionally, we collate and evaluate preclinical and clinical studies of novel immune combination regimens, and describe the prospects and perspectives for the in vivo application of novel immune technologies in patients with ALK rearranged NSCLC.
format Online
Article
Text
id pubmed-9795041
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97950412022-12-29 Current status and challenges of immunotherapy in ALK rearranged NSCLC Qi, Rongbin Yu, Yingying Shen, Mo Lv, Dongqing He, Susu Front Oncol Oncology Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase inhibitors (TKIs) but prone to drug resistance. Meanwhile, ALK rearranged NSCLC has poor response to single immunotherapy. Here we mainly describe the immune escape mechanisms of ALK mutated NSCLC and the role of related biomarkers. Additionally, we collate and evaluate preclinical and clinical studies of novel immune combination regimens, and describe the prospects and perspectives for the in vivo application of novel immune technologies in patients with ALK rearranged NSCLC. Frontiers Media S.A. 2022-12-14 /pmc/articles/PMC9795041/ /pubmed/36591504 http://dx.doi.org/10.3389/fonc.2022.1016869 Text en Copyright © 2022 Qi, Yu, Shen, Lv and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qi, Rongbin
Yu, Yingying
Shen, Mo
Lv, Dongqing
He, Susu
Current status and challenges of immunotherapy in ALK rearranged NSCLC
title Current status and challenges of immunotherapy in ALK rearranged NSCLC
title_full Current status and challenges of immunotherapy in ALK rearranged NSCLC
title_fullStr Current status and challenges of immunotherapy in ALK rearranged NSCLC
title_full_unstemmed Current status and challenges of immunotherapy in ALK rearranged NSCLC
title_short Current status and challenges of immunotherapy in ALK rearranged NSCLC
title_sort current status and challenges of immunotherapy in alk rearranged nsclc
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795041/
https://www.ncbi.nlm.nih.gov/pubmed/36591504
http://dx.doi.org/10.3389/fonc.2022.1016869
work_keys_str_mv AT qirongbin currentstatusandchallengesofimmunotherapyinalkrearrangednsclc
AT yuyingying currentstatusandchallengesofimmunotherapyinalkrearrangednsclc
AT shenmo currentstatusandchallengesofimmunotherapyinalkrearrangednsclc
AT lvdongqing currentstatusandchallengesofimmunotherapyinalkrearrangednsclc
AT hesusu currentstatusandchallengesofimmunotherapyinalkrearrangednsclc

Ejemplares similares